Leustatin

Cladribine, the active ingredient in Leustatin, is a purine nucleoside analog presented as a intravenous solution for intravenous use. It treats multiple sclerosis and hairy cell leukemia in appropriate patients.

GNH USA supplies Leustatin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Leustatin (cladribine) is indicated for conditions in which targeted depletion of lymphocytes modifies disease activity.

Multiple sclerosis: reduces annualized relapse rate and delays disability progression in adults with active disease. Hairy cell leukemia: produces durable complete remission by selectively depleting malignant B‑lymphocytes.

Cladribine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Lymphopenia: a reduction in circulating lymphocytes that may increase infection susceptibility. - Infections: mild to moderate upper respiratory or urinary tract infections occurring during treatment. - Nausea: transient nausea or vomiting, often manageable with supportive care.

Serious or Rare Side Effects: - Severe infections: opportunistic infections such as pneumocystis jirovecii pneumonia or herpesvirus reactivation. - Autoimmune disorders: emergence of autoimmune hepatitis, thyroiditis, or other organ‑specific autoimmunity. - Skin reactions: severe cutaneous adverse reactions including Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When using cladribine, several precautions should be observed to minimize risks and ensure safe administration. - Baseline assessment: obtain complete blood count and lymphocyte subsets before initiating therapy. - Infection monitoring: screen for active infections and monitor for signs of opportunistic infection during treatment. - Vaccination: avoid live vaccines during and for several weeks after therapy; update inactivated vaccines beforehand. - Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception and discuss risks with women of childbearing potential. - Renal/hepatic function: adjust use in patients with significant hepatic or renal impairment after clinical evaluation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Live vaccines: concurrent administration may cause severe infection. - Immunosuppressants: combined use can markedly increase risk of profound lymphopenia and infection. - Antiviral prophylaxis: certain antivirals may alter cladribine metabolism (e.g., strong CYP inhibitors).

Moderate Interactions (Monitor Closely): - Vaccines (inactivated): may have reduced immunogenicity; assess timing. - Anticoagulants: monitor for bleeding if thrombocytopenia develops. - Hormonal contraceptives: efficacy may be reduced; consider additional barrier methods.